• Childhood Kidney Diseases
• /
• 제8권2호
• /
• pp.256-261
• /
• 2004

저자들은 역류성 신질환 남아의 생후 6개월된 남동생을 대상으로 시행한 조기 형제선별검사에서 신손상을 보이지 않는 5단계의 좌측 방광요관역류를 발견할 수 있었다. 이후 요로감염의 발생을 방지하고자 하였으며, 이를 통하여 신손상발생의 위험을 줄일 수 있었기에 문헌고찰과 함께 보고하는 바이다. 또한 역류성 신질환 환아의 형제자매에서 방광요관역류 여부에 대한 형제선별검사를 적극적으로 시행할 것을 제안하는 바이다.

• The Korean Journal of Physiology and Pharmacology
• /
• 제13권4호
• /
• pp.295-300
• /
• 2009

It was evaluated the inhibitory action of quercetin-3-O-${\beta}$-D-glucuronopyranoside (QGC) on reflux esophagitis and gastritis in rats. QGC was isolated from the herba of Rumex Aquaticus. Reflux esophagitis or gastritis was induced surgically or by administering indomethacin, respectively. Oral QGC decreased ulcer index, injury area, gastric volume, and acid output and increased gastric pH as compared with quercetin. Furthermore, QGC significantly decreased gastric lesion sizes induced by exposing the gastric mucosa to indomethacin. Malondialdehyde levels were found to increase significantly after inducing reflux esophagitis, and were reduced by QGC, but not by quercetin or omeprazole. These results show that QGC can inhibit reflux esophagitis and gastritis in rats.

• 대한한방내과학회지
• /
• 제38권3호
• /
• pp.401-407
• /
• 2017

Objective: This study reports on a treatment case of Soojeom-san plus Jeungmiyijin-tang (SJJI) on gastroesophageal reflux disease with hiatal hernia. Method: We considered a male patient suffering from gastroesophageal reflux disease with hiatal hernia because of blood stasis and damp-heat of the spleen and stomach pattern and prescribed SJJI. The progress was evaluated using the frequency scale for the symptoms of gastroesophageal reflux disease (FSSG) score, and the visual analogue scale for abdominal pain, sore stomach, and other symptoms. Results: The patient's symptoms, which included abdominal pain, sore stomach, dyspepsia, anorexia, insomnia, etc., almost disappeared. Conclusion: SJJI can be used for patients who have a chronic condition of gastroesophageal reflux disease with hiatal hernia because of blood stasis and a pattern of damp-heat of the spleen and stomach.

• 대한한의학회지
• /
• 제44권2호
• /
• pp.70-105
• /
• 2023

This study was conducted to examine the current status of traditional korean medicine studies on gastroesophageal reflux disease in Korea, identify deficiencies, and suggest the direction of future medicine research methods to lay the foundation for traditional korean medicine treatment. All domestic papers on the korean traditional treatment of gastroesophageal reflux disease were selected among the literature published until August 2022 in six domestic databases. A total of 52 selected research data were classified into experimental research papers, clinical research papers, and review papers. In experimental papers, to evaluate the effectiveness of treatment, improvement of esophageal mucosal lesions, anti-inflammatory mechanisms, antioxidant mechanisms, esophageal mucosal protection mechanisms, gastric peristalsis control, and gastric acid secretion inhibition mechanisms were used as evaluation measures. In the clinical research paper, the basis for diagnosis of cases was clinical symptoms through medical history listening and diagnosis through visits to hospitals in the past. The average treatment period was 40.7 days, and the duration of treatment was not significantly affected by the duration of the disease. The most widely used Korean medicine treatment intervention was herbal medicine. There were 3 literature review studies, 3 systematic literature review and meta-analysis studies, 1 comparative review study for clinical trial guideline development, all using Chinese papers. This study included all domestic papers on gastroesophageal reflux disease to identify the research trend of the Korean oriental medicine community, and based on this, it is meaningful to confirm areas that need to be supplemented in future research plans.

• 핵의학기술
• /
• 제14권2호
• /
• pp.17-20
• /
• 2010

간담도 스캔은 간세포와 담낭의 기능정도 및 담도계의 폐쇄여부를 알 수 있는 검사법이다. 또한 위부분절제술 후에 증가하는 위-담즙 역류는 담즙 역류성 위염의 주요 원인으로 알려져 있다. 본 연구는 위부분절제술 환자의 간담도 스캔에서 위-담즙역류가 관찰되어 촬영방법에 따른 역류시기와 역류지표를 알아보고자 한다. 본원 핵의학과에 2008년 10월부터 2009년 1월까지 간담도 스캔을 시행한 환자 중 위부분절제술을 한 환자 72명(남자: 52명, 여자: 20명, 연령범위: 31-77세, 평균연령: $60.5{\pm}7$세)을 대상으로 하였다. $^{99m}Tc$-mebrofenin 185 MBq/0.5 cc를 환자의 전주정맥에 주사 5분 후 바로 누운자세에서 전면상 30 kcounts를 획득하고, time setting으로 우측면상, $45^{\circ}$ 좌전사 위상을 획득하였다. 동일한 방법으로 30분, 60분, 90분, 지방식 후 120분 영상을 획득하였다. 위-담즙역류가 일어난 환자의 경우 30분 전면상, 좌전사위상에서 liver, GB, CBD의 ROI를 그리고, 이후 영상들에서 위 역류 부분의 시간 별, 자세 별 관심영역을 그렸다. 그리고 그에 따른 역류지표 구하였다. 72명의 위부분절제술 환자 중 위-담즙역류가 40명(55.6%)의 환자에서 일어났으며, 30분 영상에서 1명, 60분 영상에서 7명, 90분 영상에서 4명, 지방식 후 영상에서 28명이었다. 시간 별 위-담즙역류가 최고치는 60분 영상에서 6명, 90분 영상에서 2명, 지방식 후 영상에서 32명으로 보였다. 전면상의 역류지표 0.85-23.36%(평균: 6.53%), 좌전사위상의 역류지표 1-29.13%(평균: 8.89%)이었다. 육안평가로는 26명(65%)이 전면상보다 좌전사위상의 위-담즙역류가 더 잘 구분되어 보였다. 위부분절제술 환자의 간담도 스캔에서 위-담즙역류가 50% 이상 일어나는 것을 알 수 있고, 음식물을 섭취한 후 위-담즙역류가 가장 잘 일어나는 것을 알 수 있었다. 위-담즙역류가 일어나는 경우 장과 위의 중첩을 줄여주는 좌전사위상을 촬영하고 환자마다 그에 따른 시간대의 위-담즙 역류 지표를 제공함으로써 임상에서 간담도 스캔 목적 이외의 도움이 될 것이라 생각된다.

• 대한본초학회지
• /
• 제35권4호
• /
• pp.17-23
• /
• 2020

Objectives : In this study, we investigated the protective effects of Charybdis japonica (C. japonica) water extract on the acute reflux esophagitis in rat models. Methods : Twenty rats were divided into four groups for examination: normal control group (n=6), the reflux esophagitis group (n=6), reflux esophagitis treated with positive control group (ranitidine 40 mg/kg, n=6), reflux esophagitis treated with C. japonica group (100 mg/kg, n=6). All rats fasted for 18 hr and then were induced with reflux esophagitis by a pylorus and forestomach ligation operation. After 4 hr, the rats were sacrificed. The proinflammatory cytokine and proteins expression measured by western bolt assay, and the histopathological analysis of the esophageal mucosa measured by hematoxylin and eosin staining. Results : C. japonica administration significantly was protecting esophageal mucosal damage upon histological analysis of reflux esophagitis in rats. The C. japonica treatment confirmed the protection of the reduction of claudin-5, an evaluation index of the damage of tight junctions in the reflux esophagitis. C. japonica was also found to inhibit the expression of proteins such as COX-2 and TNF-α in the rat esophagus. C. japonica markedly attenuated the activation of NF-κB and phosphorylation of IκBα at the same time. Conclusion : These results indicated that C. japonica suppressed the development of esophagitis through the modulation of inflammation by regulating NF-κB activation. Based on these findings, we concluded that C. japonica can prevent reflux esophagitis.

• Journal of Nutrition and Health
• /
• 제54권3호
• /
• pp.321-333
• /
• 2021

본 연구에서는 진피-황금 혼합물 (CS)이 급성 역류성 식도염에 미치는 식도 점막 보호 효과를 평가하기 위하여 CS를 경구투여한 후 수술을 통해 역류성 식도염을 유발하였으며, 실험 종료 후 혈액 채취 및 식도 조직을 적출하였다. 동물에게서 적출한 식도 점막의 손상 정도를 육안으로 확인한 결과 CS투여군에서 식도 점막의 손상이 유의하게 감소하였으며, H&E staining을 통해 관찰한 결과 마찬가지로 CS투여군에서 식도 상피의 탈락 및 염증세포의 침윤이 현저하게 감소한 것을 확인하였다. 혈액을 이용하여 역류성 식도염의 원인으로 유효하다고 알려진 ROS의 수치를 확인한 결과, CS투여군에서 ROS 수치가 유의적으로 감소하였으며, western blotting을 통해 NADPH oxidase인 NOX4, p47^phox, p22^phox의 발현을 확인한 결과, 마찬가지로 CS 투여군에서 유의하게 감소하였고, 특히 CS200투여군에서 Normal군과 비슷한 수치를 나타냈다. 또한, CS투여는 염증성 단백질인 MAPK와 NF-κB 경로를 유의적으로 억제하였을 뿐 아니라 tight junction 단백질인 claudin-1과 claudin-4의 발현을 유의하게 조절한 것을 확인하였다. 이상의 결과를 종합해보면 진피-황금 추출물은 산화적 스트레스를 억제함으로써 염증성 단백질의 발현을 조절할 뿐 아니라 tight junction 단백질의 발현을 조절하여 식도 점막을 보호하는 것으로 판단되나 역류성 식도염은 음식물의 섭취와 밀접한 관련이 있는 만큼 추후 동물의 식이 섭취량을 조사하는 등 세부적인 추가 연구가 필요할 것으로 보인다.

• 동의생리병리학회지
• /
• 제18권6호
• /
• pp.1933-1937
• /
• 2004

Gastroesophageal reflux disease(GERD) refers to the varied clinical manifestations of reflux of stomach and duodenal contents into the esophagus and is preferable to the 'reflux esophagitis'. Clinical symptoms of reflux esophagitis are heartburn, dysphagia, blood loss, abdominal pain, nocturnal wheezing, coughing, hoarseness. We applied oriental medicines to patient who had reflux esophagitis. we treated them with herb-medication, acupuncture, moxa therapy and aroma therapy for about 2 months. During this period, we observed that symptoms had been improved.

• 대한기관식도과학회지
• /
• 제9권1호
• /
• pp.60-66
• /
• 2003

Although there is a wide range of diseases caused by gastric acid reflux and the number of cases is on the rise, it is difficult for the laryngologist to make the correct diagnosis. The treatment for laryngopharyngeal reflux can be grouped into 3 categories - changes in lifestyle, medication, and surgery. The medication used to treat laryngopharyngeal reflux are prokinetic agents and acid supressive agents such as antacids, H2 blockers, and PPIs(Proton pump inhibitor). Rabeprazole sodium($Pariet^{\circledR}$) is a newly developed agent belonging to the PPI group, but in contrast with the existing drugs such as omeprazole, lansoprazole, pantoprazole, has a low dependency on CYP2C19 during the metabolic cycle. Thus, it is known to have a quick but fixed antiacid effect and less individual differences. We analyzed 2166 patients from 32 hospitals who were prescribed $Pariet^{\circledR}$ from May, 2001 to April, 2002. The patients were divided into 4 groups according to the duration of treatment - Group 1: 1-14 days, Group 2: 15-28 days, group 3: 29-56 days, Group 4: more than 56 days. The cases were then analyzed for improvement of 8 symptoms(heart bum, regurgitation, chronic cough, hoarseness, globus sensation, chronic throat clearing, sore throat, and dysphagia), improvement on laryngoscope, usefulness to the doctor, and complication development. Of the total of 2116 patients, 1627(75.1%) cases showed at least 50% improvement of symptoms and the amount of improvement increased according to the duration of medical treatment. Most of the patients showed objective improvement on the laryngoscope, with 32.9% showing significant improvement and 38.7% showing moderate improvement. 37.6% of the doctors questioned replied that $Pariet^{\circledR}$ was very useful and 50.3% said it was useful, showing that most were satisfied with the treatment results. The complications known to develop after taking PPI are headache, nausea, diarrhea, abdominal pain, constipation, dizziness, fatigue, and of these, only a small percentage of the patients complained of mild headache. $Pariet^{\circledR}$ has shown to be a relatively safe and effective drug for the treatment of laryngopharyngeal reflux.

• Advances in pediatric surgery
• /
• 제13권1호
• /
• pp.13-22
• /
• 2007

Fundoplication is accepted as an effective treatment of gastroesophageal reflux disease. The recent results of laparoscopic fundoplication demonstrated safety and less morbidity, shorter hospital stay and less pulmonary complication compared to the open operation. Laparoscopic fundoplication has been our first choice of operation for gastroesophageal reflux disease since 2003. Among 29 cases, there were 2 conversion cases because of severe distension of transverse colon and hepatomegaly. We studied 27 consecutive patients operated upon from January 2003 through December 2004. There were 15 boys and 12 girls, ages from 1.5 months to 12 years (median 25.3 months). Body weight ranged from 2.9 kg to 37 kg (median 9.8 kg). Neurological abnormalities were present in 23 patients. Indications for surgery included medically refractory reflux associated with vomiting, pneumopathy, otorhinolaryngologic pathology, failure to thrive, esophagitis, apnea and bradycardia. We used 4-5 trocars of 5 mm or 12 mm with $30^{\circ}$ telescope and performed the Nissen technique in all patients. In neurological impaired patients, gastrostomy tube was placed at the time of fundoplication. Median operative time was 130 minutes (70 - 300 minutes). There was no mortality nor intraoperative complication. Twenty-six patients were followed for median of 19 months (8 - 31 months). Four patients (15.4 %), who were all neurological impaired, developed recurrent symptoms of gastroesophageal reflux disease. Two of these patients had reoperation (1 laparoscopic approach, 1 open method). There were significant increases in body weight in 11 patients after fundoplication. Laparoscopic fundoplication is acceptable as a safe and effective method for gastroesophageal reflux disease.